This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Prospective, Open-label Study of Pharmacokinetics of Ertapenem in the Muscle Using Microdialysis in Mechanically Ventilated Intensive Care Unit Patients, Treated or Not by Norepinephrine

This study has been terminated.
Information provided by (Responsible Party):
Assistance Publique Hopitaux De Marseille Identifier:
First received: June 20, 2007
Last updated: February 24, 2014
Last verified: February 2014

Goal of study:

To assess the tissular and plasma kinetics of ertapenem;

To determine the optimal dosages in the patients according to norepinephrine administration:

  • to assess muscular diffusion of free form of ertapenem after administration to mechanically ventilated patients requiring such a treatment. The patients are included in the groups "with norepinephrine" or "without norepinephrine" according to their hemodynamic status.
  • to assess the plasma pharmacokinetics of ertapenem in mechanically ventilated patients treated or not by norepinephrine.

Open-label, prospective study performed in a single ICU (16 beds) of a tertiary hospital (700 beds).

Condition Intervention Phase
To Assess the Tissular and Plasma Kinetics of Ertapenem Drug: Ertapenem Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Assistance Publique Hopitaux De Marseille:

Primary Outcome Measures:
  • assess the tissular and plasma kinetics of ertapenem [ Time Frame: 24 months ]

Enrollment: 9
Study Start Date: April 2007
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Noradrenalin infusion
Drug: Ertapenem
1g a day by drip of 30 min
No Intervention: 2
No adrenalin infusion


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years and more
  • negative pregnancy test
  • HIV/HBV, HCV negative tests
  • Mechanical ventilation with pneumonia or intraabdominal infection requiring ertapenem

Exclusion Criteria:

  • refractory septic shock requiring use of additional catecholamines
  • patients with positives tests for HIV, HBV, HCV
  • pregnant females
  • allergic insufficiency
  • hemodiafiltration
  • contraindication to microdialysis catheter set-up
  • severe arteritis of lower extremities
  • treatment with vasodilatators
  • prior history of aorto-iliac shunt
  • involvement in a clinical trial in the last three months
  • exclusion from national records
  • non affiliated to "securité sociale"
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00489138

Département d'Anesthésie-Réanimation - CHU NORD
Marseille, France, 13915
Sponsors and Collaborators
Assistance Publique Hopitaux De Marseille
Principal Investigator: Ioanna BOYADJIEV, PH Assistance Publique Hôpitaux de Marseille
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Assistance Publique Hopitaux De Marseille Identifier: NCT00489138     History of Changes
Other Study ID Numbers: 2006/24
Study First Received: June 20, 2007
Last Updated: February 24, 2014

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents processed this record on September 21, 2017